Sutro Biopharma, Inc.
STRO Real Time Price USDRecent trades of STRO by members of U.S. Congress
|
Name
|
Type
|
Shares
|
Price
|
Shares Held
|
Date
|
Reported
|
|---|
|
Investor
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
|
Investor
|
Type
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
Recently reported changes in STRO holdings by institutional investors
Quarterly net insider trading by STRO's directors and management
* Insider trading data parsed from SEC Form 4 filings by Quiver Quantitative. Sign up for the Quiver API for real-time access.
- 1M
- 3M
- 6M
- YTD
- 1Y
- 2Y
- 5Y
- MAX
About
Key Metrics
Return (1d)
Return (30d)
Return (1Y)
CAGR (Total)
Max Drawdown
Beta
Alpha
Sharpe Ratio
Win Rate
Average Win
Average Loss
Annual Volatility
Annual Std Dev
Information Ratio
Treynor Ratio
Total Trades
Metrics Definitions
-
Alpha
Measures a portfolio's risk-adjusted performance against that of its benchmark
Learn More -
Annual Standard Deviation
Measures how much the portfolio's total return varies from its mean or average.
Learn More -
Annual Volatility
A statistical measure of the dispersion of returns for the portfolio.
Learn More -
Average Win
The average return (%) for trades that resulted in a positive return.
-
Average Loss
The average return (%) for trades that resulted in a negative return.
-
Beta
A measure of the volatility of the portfolio compared to the market as a whole.
Learn More -
CAGR
CAGR (Compounded Annual Growth Rate), is the historical annualized rate of return for an investment strategy, throughout the backtest period.
Learn More -
Information Ratio
A measurement of portfolio returns beyond the returns of its benchmark compared to the volatility of those returns.
Learn More -
Max Drawdown
the maximum observed loss from a peak to a trough of a portfolio, before a new peak is attained.
Learn More -
Sharpe Ratio
The Sharpe Ratio is a measure of historical risk-adjusted return, which quantifies the amount of return that an investor received per unit of risk.
Learn More -
Total Trades
The total number of trades made by this strategy.
-
Treynor Ratio
Attempts to measure how successful an investment is in providing compensation to investors for taking on investment risk.
Learn More -
Win Rate
The percentage of total trades that resulted in a positive return.
Be the first to see our newest insights and key updates across all datasets.
Government lobbying spending instances
STRO Estimated quarterly lobbying spending
STRO Revenue by Segment or Geography
New STRO patent grants
-
Patent Title: Anti-folate receptor antibody conjugates, compositions comprising anti-folate receptor antibody conjugates, and methods of making and using anti-folate receptor antibody conjugates Sep. 30, 2025
-
Patent Title: 5h-pyrrolo[3,2-d]pyrimidine-2,4-diamino compounds and antibody conjugates thereof Sep. 23, 2025
-
Patent Title: Antibodies with engineered ch2 domains, compositions thereof and methods of using the same Aug. 26, 2025
-
Patent Title: Methods of producing full-length antibodies using Jul. 08, 2025
-
Patent Title: Modified amino acids Apr. 08, 2025
-
Patent Title: Modified fc proteins comprising site-specific non-natural amino acid residues, conjugates of the same, methods of their preparation and methods of their use Mar. 18, 2025
-
Patent Title: Anti-ror1 antibody conjugates, compositions comprising anti ror1 antibody conjugates, and methods of making and using anti-ror1 antibody conjugates preliminary class Feb. 18, 2025
-
Patent Title: Anti-ror1 antibody conjugates, compositions comprising anti ror1 antibody conjugates, and methods of making and using anti-ror1 antibody conjugates Nov. 19, 2024
-
Patent Title: Formulations for drying bacterial cell extracts Sep. 24, 2024
-
Patent Title: Anti-folate receptor alpha antibody conjugated with hemiasterlins Aug. 27, 2024
-
Patent Title: Anti-bcma antibodies and treatment methods May. 28, 2024
-
Patent Title: Antibodies comprising site-specific non-natural amino acid residues, methods of their preparation and methods of their use Apr. 16, 2024
-
Patent Title: Hemiasterlin derivatives for conjugation and therapy Jan. 09, 2024
-
Patent Title: Immunomodulator antibody drug conjugates and uses thereof Sep. 05, 2023
-
Patent Title: Anti-cd74 antibody conjugates, compositions comprising anti-cd74 antibody conjugates and methods of using anti-cd74 antibody conjugates Jul. 25, 2023
-
Patent Title: Modified amino acids Jan. 10, 2023
-
Patent Title: Formulations for drying bacterial cell extracts Aug. 09, 2022
-
Patent Title: Antibodies comprising multiple site-specific non-natural amino acid residues, methods of their preparation and methods of their use May. 31, 2022
-
Patent Title: Proteolytic inactivation of select proteins in bacterial extracts for improved expression Mar. 01, 2022
-
Patent Title: Anti-epcam antibodies, compositions comprising anti-epcam antibodies and methods of making and using anti-epcam antibodies Aug. 24, 2021
-
Patent Title: Antibodies with engineered ch2 domains, compositions thereof and methods of using the same Aug. 24, 2021
-
Patent Title: Anti-tim-3 antibodies, compositions comprising anti-tim-3 antibodies and methods of making and using anti-tim-3 antibodies May. 25, 2021
-
Patent Title: Anti-cd74 antibodies, compositions comprising anti-cd74 antibodies and methods of using anti-cd74 antibodies Apr. 13, 2021
-
Patent Title: Hemiasterlin derivatives for conjugation and therapy Nov. 24, 2020
-
Patent Title: Anti-pd-1 antibodies, compositions comprising anti-pd-1 antibodies and methods of using anti-pd-1 antibodies Nov. 03, 2020
-
Patent Title: Expression of biologically active proteins in a bacterial cell-free synthesis system using bacterial cells transformed to exhibit elevated levels of chaperone expression Sep. 15, 2020
-
Patent Title: Use of lambda-gam protein in ribosomal display technology Aug. 04, 2020
-
Patent Title: Modified amino acids Aug. 04, 2020
-
Patent Title: Antibodies comprising site-specific non-natural amino acid residues, methods of their preparation and methods of their use Jun. 02, 2020
-
Patent Title: Formulations for drying bacterial cell extracts May. 12, 2020
-
Patent Title: Anti-folate receptor antibody conjugates, compositions comprising anti-folate receptor antibody conjugates, and methods of making and using anti-folate receptor antibody conjugates Mar. 24, 2020
-
Patent Title: Modified fc proteins comprising site-specific non-natural amino acid residues, conjugates of the same, methods of their preparation and methods of their use Dec. 10, 2019
-
Patent Title: Codon optimization for titer and fidelity improvement Nov. 26, 2019
-
Patent Title: Proteolytic inactivation of select proteins in bacterial extracts for improved expression Oct. 22, 2019
-
Patent Title: Modified amino acids comprising tetrazine functional groups, methods of preparation, and methods of their use Oct. 15, 2019
-
Patent Title: High growth capacity auxotrophic Jun. 11, 2019
-
Patent Title: Expression of biologically active proteins in a bacterial cell-free synthesis system using bacterial cells transformed to exhibit elevated levels of chaperone expression Jan. 29, 2019
-
Patent Title: Non-natural amino acid trna synthetases for pyridyl tetrazine Jan. 15, 2019
-
Patent Title: Modified amino acids Jun. 12, 2018
-
Patent Title: Non-natural amino acid trna synthetases for pyridyl tetrazine Jun. 05, 2018
-
Patent Title: Non-natural amino acid trna synthetases for para-methylazido-l-phenylalanine Apr. 10, 2018
-
Patent Title: Use of lambda-gam protein in ribosomal display technology Feb. 20, 2018
-
Patent Title: Modified amino acids comprising tetrazine functional groups, methods of preparation, and methods of their use Dec. 12, 2017
-
Patent Title: Antibodies comprising multiple site-specific non-natural amino acid residues, methods of their preparation and methods of their use Sep. 19, 2017
-
Patent Title: Antibodies comprising site-specific non-natural amino acid residues, methods of their preparation and methods of their use Aug. 22, 2017
-
Patent Title: Modified fc proteins comprising site-specific non-natural amino acid residues, conjugates of the same, methods of their preparation and methods of their use Aug. 15, 2017
-
Patent Title: Modified amino acids Jun. 20, 2017
-
Patent Title: Proteolytic inactivation of select proteins in bacterial extracts for improved expression May. 16, 2017
-
Patent Title: Method for enhancing recombinant protein production by cell-free protein expression system May. 26, 2015
-
Patent Title: Mono charging system for selectively introducing non-native amino acids into proteins using an in vitro protein synthesis system Jul. 15, 2014
Federal grants, loans, and purchases
Estimated quarterly amount awarded to STRO from public contracts
Recent insights relating to STRO
Recent picks made for STRO stock on CNBC
ETFs with the largest estimated holdings in STRO
- ... Highest Price Target
- ... Median Price Target
- ... Lowest Price Target
|
Analyst
|
Firm
|
Current
|
Previous
|
Date
|
|---|
- Is $STRO stock a Buy, Sell, or Hold?
- What is the price target for $STRO stock?
* Analyst consensus is not financial advice. Please see our data disclaimers .
|
Shareholder
|
Shares Held
|
|---|
- Who owns $STRO stock?
- Who owns the most shares of $STRO stock?
- What funds own $STRO stock?
* These are estimates based on data taken from SEC filings. There may be inaccuracies due to parsing errors, accidental double-counting, incorrect classification of indirectly owned shares, or any other number of issues.
The Quiver Smart Score combines our data on Congress Trading, Lobbying, Insider Trading, CNBC Mentions and more to provide a comprehensive view of the strength of a stock's underlying data.
The Smart Score grades stocks on a scale of 1 (weakest) to 10 (strongest) based on the strength of the underlying data.Sign Up to view STRO Smart Score
See concise summaries of analyst reports, presenting both bullish and bearish arguments for a stock.
Example:
The Bulls Say summary highlights positive aspects of the stock.
The Bears Say summary points out potential risks and negative aspects of the stock.
Sutro Biopharma Inc is a clinical-stage drug discovery, development, and manufacturing company. It is mainly engaged in the development of biopharmaceutical products. The company manufactures next-generation protein therapeutics for cancer and autoimmune disorders through its proprietary integrated cell-free protein synthesis platform, XpressCF. Products offered by the company include STRO-001 for patients with multiple myeloma and non-Hodgkin lymphoma and STRO-002 for the treatment of ovarian and endometrial cancers. The company also pipeline contains STRO-004, STRO-006, STRO-00X, STRO-00Y, STRO-003, VAX24, VAX31, and Others.
- Address South San Francisco, CA
- Market Cap 71.8 million
- Employees 131
- Industrial Classification Biological Products, (No Disgnostic Substances)